RTP Mobile Logo
Oncology Today with Dr Neil Love: Novel Agents and Strategies for the Treatment of Metastatic Castration-Resistant Prostate Cancer (Audio Interview)
Released January 2022

Featuring an interview with Dr Evan Yu. Published January 22, 2022. (Audio Interview)

CE Disclosures and Faculty Information

    This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of prostate cancer.


    • Assess available and emerging research data surrounding the optimal management of metastatic castration-resistant prostate cancer (mCRPC), and apply recent advances to current clinical care.
    • Establish an evidence-based approach to the selection, sequencing or combining of available therapeutic options for patients with mCRPC considering age, comorbidities, prior therapeutic exposure and other relevant clinical and biologic factors.
    • Describe the rationale for testing patients with mCRPC for BRCA1/2 or other related mutations, and advise individuals found to harbor these genetic abnormalities about available data documenting the efficacy of PARP inhibition in specific settings.
    • Evaluate the recent FDA approvals of olaparib and rucaparib for mCRPC, and optimally incorporate these agents into clinical algorithms.
    • Appreciate emerging Phase III data documenting the efficacy of 177Lu-PSMA-617 in patients with progressive, PSMA-positive mCRPC, and consider the potential future clinical role of this strategy.
    • Recall the design of ongoing clinical trials evaluating other novel agents and strategies for mCRPC, and counsel appropriate patients about availability and participation.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    Audio Program: This CME activity consists of an audio component.
    CME credit is no longer available for this issue

    Video Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Evan Y Yu, MD
    Professor of Medicine
    Division of Oncology, Department of Medicine
    University of Washington School of Medicine
    Member, Clinical Research Division
    Fred Hutchinson Cancer Research Center
    Medical Director, Clinical Research Services
    Fred Hutchinson Cancer Research Consortium
    Seattle, Washington

    Advisory Committee: Advanced Accelerator Applications, Bayer HealthCare Pharmaceuticals, Clovis Oncology, Exelixis Inc, Janssen Biotech Inc, Merck; Contracted Research: Bayer HealthCare Pharmaceuticals, Blue Earth Diagnostics, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Lantheus, Merck, Seagen Inc, Taiho Oncology Inc.

    EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Exelixis Inc, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications and Sanofi Genzyme.

    Release date: January 2022
    Expiration date: January 2023

Acknowledge and close

Listen to interview
(WIFI is recommended for best performance):